EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

23 April 2026
EMADOC-1700519818-3288349
Committee for Medicinal Products for Human Use (CHMP)

Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Active substance(s): cenobamate

Procedure No. PSUSA/00010921/202509

Period covered by the PSUR: 1 year to 26 September 2025

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Scientific conclusions

Taking into account the PRAC Assessment Report on the PSUR(s) for cenobamate, the scientific conclusions of PRAC are as follows:

In view of available data on cenobamate-associated liver injury from clinical trial(s), the literature and spontaneous reports including in some cases a close temporal relationship, a positive de-challenge and in view of a plausible mechanism of action, the PRAC considers a causal relationship between cenobamate and liver injury is at least a reasonable possibility. The PRAC concluded that the product information of products containing cenobamate should be amended accordingly.

Having reviewed the PRAC recommendation, the CHMP agrees with the PRAC overall conclusions and grounds for recommendation.

Grounds for the variation to the terms of the marketing authorisation(s)

On the basis of the scientific conclusions for cenobamate the CHMP is of the opinion that the benefit-risk balance of the medicinal product(s) containing cenobamate is unchanged subject to the proposed changes to the product information

The CHMP recommends that the terms of the marketing authorisation(s) should be varied.